Gabapentin (CAS 60142-96-3) is an anticonvulsant and analgesic API widely used for the management of partial seizures, postherpetic neuralgia and other neuropathic pain conditions. Although structurally related to γ-aminobutyric acid (GABA), it does not bind directly to GABA receptors. Instead, gabapentin binds with high affinity to the α2δ-1 subunit of voltage-gated calcium channels, reducing calcium influx at presynaptic terminals and decreasing the release of excitatory neurotransmitters involved in pain and seizure transmission.
Gabapentin 60142-96-3 from TCS INDUSTRIES LIMITED is supplied as a high-purity Active Pharmaceutical Ingredient suitable for immediate-release and modified-release oral formulations. It is commonly formulated into capsules, tablets and oral solutions. Because gabapentin exhibits dose-dependent pharmacokinetics and saturable absorption, formulation and dosing strategies must be carefully aligned with clinical requirements.
Within the TCS
Active Pharmaceutical Ingredient
portfolio, gabapentin is often grouped with other central nervous system (CNS) APIs used in psychiatry and neurology. For example:
- Clomipramine 303-49-1 – a tricyclic antidepressant frequently used in obsessive-compulsive disorder and depression, often in patients who may also have chronic pain or sleep issues.
- Coenzyme Q10 303-98-0 – a mitochondrial cofactor widely used in nutraceuticals for energy and neuroprotection concepts that can complement long-term neurological care.
Gabapentin formulations benefit from well-chosen fillers, binders and disintegrants to achieve consistent content uniformity and rapid dissolution, particularly at high dosage strengths. TCS INDUSTRIES LIMITED offers a range of
that can be matched with gabapentin’s physical properties to facilitate direct compression or granulation processes and to manage hygroscopicity or flow.
With robust quality control, detailed technical documentation and experience in CNS actives, TCS GROUP enables manufacturers to develop reliable gabapentin products that meet regulatory expectations and support patients with epilepsy and neuropathic pain worldwide.